WordNet

a circumscribed inflammatory and often suppurating lesion on the skin or an internal mucous surface resulting in necrosis of tissue (同)ulceration

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 口腔病変 oral lesions
2. ベーチェット症候群の臨床症状および診断 clinical manifestations and diagnosis of behcets syndrome
3. ベーチェット症候群の治療 treatment of behcets syndrome
4. 若齢小児におけるヘルペス性歯肉口内炎 herpetic gingivostomatitis in young children
5. 小児におけるセリアック病の診断 diagnosis of celiac disease in children

Kutsuna S, Ohmagari N, Tanizaki R, Hagino N, Nishikomori R, Ujiie M, Takeshita N, Hayakawa K, Kato Y, Kanagawa S.SourceNational Center for Global Health and Medicine, Disease Control and Prevention Center , Shinjuku-ku, Tokyo , Japan.
Modern rheumatology / the Japan Rheumatism Association.Mod Rheumatol.2013 Dec 2. [Epub ahead of print]
A 26-year-old woman presented with fever and pharyngitis. She previously experienced four periodic febrile episodes at 30- to 40-day intervals. We suspected periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome, and prescribed predisolone, thereby her fever rapidly subsided
PMID 24289199

Profile of inflammatory mediators in tonsils of patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome.

Valenzuela PM, Araya A, Pérez CI, Maul X, Serrano C, Beltrán C, Harris PR, Talesnik E.SourceDivision of Pediatrics, Facultad de Medicina, Pontificia Universidad Católica de Chile, Lira 85, 5th floor, Santiago, Chile, pvalenzu@med.puc.cl.
Clinical rheumatology.Clin Rheumatol.2013 Dec;32(12):1743-9. doi: 10.1007/s10067-013-2334-z. Epub 2013 Jul 23.
The purpose of this study was to analyze the levels of white blood cells and profile of proinflammatory Th1, Th2, Th17, and T regulatory tissue cytokines in the tonsils of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) patients to contribute to the pathophysiological
PMID 23877488

Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, van Erp NP, Gelderblom H.SourceDepartment of Clinical Oncology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands.
Future oncology (London, England).Future Oncol.2013 Dec;9(12):1883-92. doi: 10.2217/fon.13.141.
With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-ass
PMID 24295418